3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
13
Observational
2
Sponsor
Cancer Type
Other hematologic neoplasm
9
Lymphoid
4
Plasma cell
2
Myeloid
1
Genitourinary
1
Classical hematology
1
Conditions
Multiple Myeloma
463
Neoplasms, Plasma Cell
81
Lymphoma
75
Leukemia
51
Lymphoma, Non-Hodgkin
49
Leukemia, Lymphocytic, Chronic, B-Cell
45
Myelodysplastic Syndromes
43
Immunoglobulin Light-chain Amyloidosis
42
Leukemia, Myeloid, Acute
39
Hodgkin Disease
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
33
Neoplasms
32
Hematologic Neoplasms
31
Breast Neoplasms
31
Myeloproliferative Disorders
29
Lymphoma, Large B-Cell, Diffuse
29
Lymphoma, Follicular
29
Monoclonal Gammopathy of Undetermined Significance
28
Smoldering Multiple Myeloma
25
Lymphoma, Mantle-Cell
25
Lymphoma, B-Cell, Marginal Zone
24
Recurrence
23
Burkitt Lymphoma
21
Amyloidosis
21
Prostatic Neoplasms
20
Lymphoma, T-Cell, Cutaneous
20
Lymphoma, Large-Cell, Immunoblastic
19
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
19
Waldenstrom Macroglobulinemia
18
Sezary Syndrome
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Observational
×
Leukemia, Lymphoid
×
Plasma cell
×
Clear all
NCT02434484
2021-01-26
Symbenda Post-Marketing Surveillance (PMS)
Eisai Inc.
Completed
84 enrolled
NCT02885038
2017-10-02
TCP
Etablissement Français du Sang
Completed
1,101 enrolled